Stock Movers: Constellation Energy, Moderna, Marvell (Podcast)

Constellation Energy shares rose after Google and Constellation announced a long-term deal to add 890 MW of nuclear capacity to the PJM grid in Illinois, Pennsylvania and New Jersey. Marvell shares climbed as much as 11% after it raised fiscal 2028 revenue guidance to $20 billion, above the average analyst estimate, while Vaxcyte, Moderna and Revolution Medicines were among the biotech stocks posting steep losses.

Analysis

The nuclear agreement’s investable value depends less on headline megawatts than on contract economics: price, duration, who bears construction and delivery risk, and whether the capacity is genuinely incremental. If those terms support financing and delivery, CEG could gain a template for monetizing nuclear output as data-center demand tightens PJM supply; competing generators may benefit from improved bargaining power, while large power buyers face higher procurement costs. But a long-term buyer commitment does not by itself establish CEG’s returns or remove permitting and execution risk. For GOOG, the deal is a potential hedge against power scarcity, not evidence that its broader AI costs are falling.

MRVL’s raised FY2028 outlook is a positive demand signal, but the long lead time makes order quality, customer concentration, and conversion to cash flow more important than the estimate-beating headline. Confirmation in subsequent quarterly guidance matters; semiconductor suppliers and peers may see sentiment spillover, but not necessarily equivalent earnings leverage.

The biotech selloff offers no company-specific explanation or evidence that clinical prospects changed. Near-term conference catalysts can widen dispersion rather than lift the group uniformly. A broad dip-buy is premature absent asset-level data. Immediate reactions may persist for days; contract disclosures and earnings updates matter over 1–3 months, while nuclear buildout and data-center power constraints are a multi-year theme.

Key Decisions for Investors

• CEG: Treat strength as conditional, not a reason to chase. Review the power purchase agreement and filings for term, pricing, incremental capacity, capital obligations, and approvals; consider a starter position only if economics are attractive and delivery risk is allocated. Reassess if terms disappoint or project milestones slip.
• GOOG: Monitor power-cost disclosures and incremental data-center commitments. The thesis weakens if the agreement proves immaterial to its load or if power procurement costs continue to pressure investment returns; avoid treating this single deal as a broad earnings catalyst.
• MRVL: Prefer waiting for the next quarterly report to test whether FY2028 guidance is supported by bookings, customer breadth, and cash conversion. A pullback with guidance intact is a better entry than chasing the gap; trim or avoid if subsequent outlook fails to confirm the long-dated target.
• MRNA, PCVX, and RVMD: No dip-buy based solely on the sector move. Track company-specific clinical updates and conference disclosures; use defined-risk exposure around binary events only after verifying trial timelines and data, which are not provided here.